Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$4.17 USD
-0.12 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Corvus Pharmaceuticals, Inc.'s return on equity, or ROE, is -24.04% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that CRVS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CRVS 4.17 -0.12(-2.80%)
Will CRVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVS
Corvus Pharmaceuticals Q2 2025 Earnings Preview
Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News
Corvus announces IND application approved by CDE of China NMPA to start trial
Corvus announces IND application approved by CDE of China NMPA to start trial
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)